NuVasive Announces Educational Initiatives In Support Of Spine’s Fastest Growing Spinal Deformity Portfolio

SAN DIEGO, CA – May 22, 2017 – NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the Company’s increased investment and support of adult and pediatric deformity research, education, and awareness initiatives throughout 2017.

NuVasive increased its focus on the $2.5 billion deformity market in May 2015 with the launch of its Integrated Global Alignment® (iGA®) platform and RELINE® posterior fixation system. In February 2016, NuVasive expanded its footprint into the early onset scoliosis market with the addition of its industryleading MAGEC® system, which utilizes innovative magnetic technology within adjustable growing rods. Today, NuVasive has the fastest growing spinal deformity portfolio and is expanding its support of key programs to drive improved clinical and economic outcomes. NuVasive recently launched the ‘Embracing the Journey Together’ program, which includes pediatric spinal deformity research, education and spinal deformity event support, supporting leading surgeons as they educate surgeons around the world.

“At NuVasive, we remain laser-focused on transforming the lives of patients through disruptive innovation and support of clinical education and research,” said Greg Lucier, NuVasive chairman and chief executive officer. “We’ve made tremendous gains in adult and pediatric spinal deformity innovation, with the versatile RELINE portfolio and MAGEC system. With the upcoming launch of the RELINE Small Stature system available this summer, I’m confident in our ability to outpace the market. We’re proud NuVasive has taken the lead in supporting key global initiatives designed to help improve the lives of patients around the world.”

Part of the Company’s investment into pediatric spinal deformity care includes funding research and patient initiatives, such as the Harms Study Group and its Setting Scoliosis Straight Foundation, as the exclusive sponsor of the Power Over Scoliosis event. NuVasive is also providing research funding for the Children’s Spine Study Group and the Growing Spine Study Group.

NuVasive was a key sponsor of EPOSNA 2017, the combined meeting of EPOS and POSNA, held earlier this month in Barcelona, Spain. In July, NuVasive is the leading sponsor of IMAST 2017, the International Meeting on Advanced Spine Techniques hosted by the Scoliosis Research Society. The Company is also the leading sponsor of ICEOS, the International Congress of Early-onset Scoliosis, in November.

The Company also announced the launch of a monthly podcast series, MAGEC Matters, featuring interviews with leading surgeons in pediatric deformity discussing tips for the treatment of early onset scoliosis, which is now available on iTunes, SoundCloud and other leading podcast platforms.

Other events supported by NuVasive throughout 2017 include:

  • Setting Scoliosis Straight: Patient & Family Power over Scoliosis Educational Event June 2-3, 2017; Miami
  • Shriners Hospital for Children – Chicago “Early Onset Scoliosis and Management Strategies” Meeting June 9, 2017; Chicago
  • International Meeting on Advanced Spine Techniques (IMAST) July 12-15, 2017; Cape Town, South Africa
  • Scoliosis Research Society (SRS) Sept. 6-9, 2017; Philadelphia
  • Pediatric Orthopedic Surgical Techniques Lab (POST) Sept. 29-30, 2017; Memphis, Tenn.
  • International Congress of Early-onset Scoliosis (ICEOS) Nov. 16-17; 2017, San Diego
  • 2017 MAGEC Users Meeting Nov. 17-18, 2017; San Diego
  • International Pediatric Orthopaedic Symposium (IPOS) Nov. 28-Dec 2, 2017; Orlando, Fla.
  • Spina Bifida Association Walk-n-Roll Events Various U.S. cities throughout 2017

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

# # #

Investor Contact:
Suzanne Hatcher
NuVasive, Inc.
858-458-2240
investorrelations@nuvasive.com

Media Contact:
Stefanie Mazer
NuVasive, Inc.
858-320-5243
media@nuvasive.com

Previous PostNext Post